216
Participants
Start Date
October 5, 2021
Primary Completion Date
October 20, 2022
Study Completion Date
October 20, 2022
Rifaximin
Rifaximin tablets
Placebo
Placebo tablets
JUVA Skin and Laser Center, New York
Paddington Testing Co, Inc, Philadelphia
West End Dermatology Associates, Richmond
Dermatology Consulting Services, PLLC, High Point
Onsite Clinical Solutions, Charlotte
DelRicht Research, Marietta
Leavitt Medical Associates of Florida, Ormond Beach
Savin Medical Group, Miami Lakes
Sweet Hope Research Specialty, Inc., Hialeah
Skin Care Research, Boca Raton
MOORE Clinical Research,Inc., Brandon
DS Research, Louisville
DS Research, Clarksville
Revival Research Institute, LLC., Troy
Grekin Skin Care Institute, Wyandotte
MediSearch Clinical Trials, Saint Joseph
DelRicht Research, New Orleans
DelRicht Research Houma Louisiana, Houma
Delricht Research Covington LA, Covington
Delricht Research Baton Rouge LA, Baton Rouge
Johnson Dermatology, Fort Smith
DelRicht Research, Tulsa
DelRicht Research Frisco Texas, Frisco
Dermatology Treatment and Research Center, Dallas
Progressive Clinical Research, San Antonio
Austin Institute for Clinical Research, Pflugerville
3A Research, El Paso
Velocity Clinical Research, Salt Lake City
Dermatology Research Ventures, Yuma
JDR Dermatology Research, Las Vegas
Metropolis Dermatology, Los Angeles
LA Universal Research Center, Los Angeles
Long Beach Clinical Trials, Long Beach
Cosmetic Laser Dermatology, San Diego
UCSD, San Diego
University Clinical Trials, Inc., San Diego
Oregon Dermatology and Research Center, Portland
Skin Science PLLC, Louisville
Lead Sponsor
bioRASI, LLC
INDUSTRY
Alfasigma S.p.A.
INDUSTRY